Emfilermin

Summary

Emfilermin is an investigational recombinant form of human leukemia inhibitory factor (LIF), a cytokine of the interleukin‑6 family. Administered by subcutaneous injection, it has been studied primarily in oncology settings to influence blood cell recovery after chemotherapy and, more recently, to test whether it can prevent chemotherapy‑induced peripheral neuropathy.

Mechanism of Action

Emfilermin binds the LIF receptor complex, which consists of LIFRβ and the shared gp130 subunit. This triggers JAK‑STAT3 signaling and downstream transcriptional programs that promote hematopoietic progenitor proliferation, acute‑phase protein production, and anti‑apoptotic effects. The same pathways are thought to modulate neuronal survival, which led to trials investigating neuropathy protection.

What the Research Shows

Pharmacokinetic modelling in post‑menopausal women and IVF patients showed rapid subcutaneous absorption (≈0.8 h) and a moderate‑to‑high volume of distribution, with clearance affected by body weight. A phase I study in advanced‑cancer patients demonstrated biologic activity: increased platelet counts, earlier platelet recovery, reduced neutrophil nadir after chemotherapy, and elevations in C‑reactive protein. Autonomic effects (impotence, episodic hypotension) and dose‑limiting hypotension/rigors were reported. A subsequent phase II, double‑blind, placebo‑controlled trial in solid‑tumour patients receiving carboplatin/paclitaxel found no difference in electrophysiologic or clinical measures of peripheral neuropathy, indicating no protective benefit in that setting.

Reported Benefits

Early‑phase data suggest Emfilermin can accelerate hematopoietic recovery after myelosuppressive chemotherapy, as reflected by faster platelet rebound and less severe neutropenia in higher‑dose cohorts. These effects point to a potential role in supporting blood cell regeneration during cancer treatment, although efficacy has not been confirmed in larger trials.

Limitations of the Evidence

Evidence is limited to small phase I and a single phase II trial; no large‑scale efficacy data exist. The neuropathy study showed no clinical benefit, and the hematopoietic findings remain exploratory. Pharmacokinetics reveal a short half‑life (1–5 h), requiring frequent dosing, and body‑weight‑dependent clearance adds dosing complexity. Overall, the therapeutic value of Emfilermin remains unproven.

Safety Considerations

Phase I participants experienced dose‑limiting hypotension, rigors, and autonomic disturbances such as impotence and episodic low blood pressure. Increases in C‑reactive protein were common at higher doses. The neuropathy trial reported good tolerability with 95 % compliance and no quality‑of‑life impact, but systematic safety data are sparse. Monitoring for cardiovascular and autonomic side effects is advisable in future studies.

How It Is Administered

Emfilermin is administered by subcutaneous injection. Clinical protocols have used daily dosing for 7 days before chemotherapy or for up to 14 days after chemotherapy, with doses ranging from 0.25 to 16 µg/kg. The drug is supplied as a recombinant protein formulation suitable for injection.

Routes of Administration

Goals & Uses

• Improvement of dyslipidemiaMetabolicLow
• NASH treatmentHepaticModerate
• Reduction of hepatic steatosisMetabolicModerate

Contraindications

• Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• HeadacheNeurologicUncommonPain in the head or upper neck
• Elevated LDL cholesterolLaboratoryUnknown
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Injection site erythemaLocalCommonRedness at the injection site

Drug Interactions

• Cytochrome P450 substratesLow

Population Constraints

• Pediatric patients (<18 years)AgeAbsolute
• Renal impairment (eGFR <30 mL/min)RenalRelative

Regulatory Status

• European UnionInvestigationalClinical development under EMA oversight.
• United StatesInvestigationalPhase 2/3 trials ongoing for NASH.

Currently in Phase 2/3 clinical development; not approved in any jurisdiction.

Evidence & Sources

• Gateways to clinical trials
  Journal ArticleLowBayes M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
• Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer
  Journal ArticleModerateGoggin T, Nguyen QT, Munafo A2004-01-01T00:00:00.000000Z
• A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
  Journal ArticleUngradedWen PY2005-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayés M, Rabasseda X, Prous JR2003-01-01T00:00:00.000000Z
• A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy
  Journal ArticleModerateDavis ID, et al.2005-01-01T00:00:00.000000Z
• A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer
  Journal ArticleModerateGunawardana DH, et al.2003-01-01T00:00:00.000000Z

Frequently Asked Questions